American Urological Association Showcase

2nd June 2010

Plethora Solutions Holdings plc

("Plethora" or "the Company")

Plethora Products "Showcased" at The American Urological Association Annual Meeting

Plethora Solutions Holdings plc (AIM: PLE), the UK-based specialty pharmaceutical company, announces that two of Company's products, PSD502 for premature ejaculation (PE) and PSD503 for stress urinary incontinence have featured prominently at the prestigious American Urological Association (AUA) annual meeting in San Francisco. Presentations of the double blind placebo controlled clinical studies of PSD502 and PSD503 were made in a session entitled "late breaking science and clinical data". These papers were two of less than 20 key abstracts selected from the many thousands submitted for oral presentation in the session. A further 4 oral presentations on PSD502 were made in other sessions in the conference.

Dr Mike Wyllie, Plethora CSO, commented: "The inclusion of both products for presentation in one of the most important sessions in the AUA reflects the high quality of the PSD502 and PSD503 data and also re-enforces the recognition by the urological community that both stress incontinence and PE are areas of significant medical need."

-Ends-

Enquiries:

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of therapeutic products for the treatment of urology, andrology and obstetric conditions. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L).

Further information is available at www.plethorasolutions.co.uk.